JPRN-jRCT2080221834UnknownPhase 1
A phase I study of YHI-1001 in patients with solid tumors
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Yakult Honsha Co., Ltd.
- Enrollment
- 18
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 74age old (—)
- Sex
- All
Inclusion Criteria
- •(1)Patients with histologically and cytologically confirmed solid tumors
- •(2)Patients who have completed conventional therapies for their tumors or patients with tumors for which no conventional therapy exists
- •(3)ECOG performance status (PS) :0-1
- •(4) Patients who are able to take YHI-1001 orally and do not have GI dysfunction judged to have impact on abosorption of YHI-1001
Exclusion Criteria
- •(1)Patients who have taken HDAC inhibitors
- •(2)Patients with significant cardiovascular disease
- •(3)Patients with symptomatic brain metastatis requiring treatment
Investigators
Similar Trials
Unknown
Phase 1
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapyJPRN-jRCT2080222078Yakult Honsha Co., Ltd.164
Unknown
Phase 1
Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapyPatients with non-small cell lung cancer who have received platinum-based chemotherapyJPRN-jRCT2080222077Yakult Honsha Co., Ltd.118
Unknown
Phase 1
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18
Suspended
Phase 1
A Phase I Study of CYT001Cancer peptide vaccineHepatocellular carcinomaJPRN-jRCT2031190072Kato Naoya6
Recruiting
Phase 1
A Phase 1 study of RN-1101JPRN-jRCT2031220477Yoshimatsu Kentaro88